Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of FL058 and Meropenem in Healthy Subjects
NCT05058105Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pralubactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (5 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Number of patients with adverse events. Started Oct 2020; status: completed.
02
Drugs
pralubactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT05058105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058105.